A-S Medication Solutions

Farmaceutisch bedrijf56 producten gevolgd

producten gevolgd

3.447.028

totaal meldingen

425

recalls geregistreerd

65,4%

ernstig algeheel

Producten

56 van 56 getoond

Product	Goedgekeurd	Meldingen ↓	Top signaal	Recalls
prednisone —	1972	491.157	systemische lupus erythematosus	11
levothyroxine sodium —	2000	308.680	Hartkloppingen	100
ibuprofen capsules 200 mg —	—	195.145	chronische nierziekte	1
montelukast —	2012	171.338	astma	14
naproxen —	1987	162.981	synovitis	12
spironolactone —	1979	137.410	hyperkaliëmie	11
levetiracetam —	2003	130.496	Resistentie tegen meerdere geneesmiddelen	18
celecoxib —	1998	129.432	psoriatische artropathie	4
diazepam —	1963	119.417	medicijnmisbruik	13
montelukast sodium —	2012	118.894	obstructieve luchtwegaandoening	14
formoterol fumarate dihydrate —	2006	114.158	obstructieve luchtwegaandoening	2
amoxicillin —	1974	99.955	ernstige nierziekte	20
tadalafil —	2019	98.103	Pulmonale arteriële hypertensie	0
budesonide and formoterol fumarate dihydrate —	—	95.176	obstructieve luchtwegaandoening	1
dulaglutide —	2014	86.770	Onopzettelijk te lage dosis	3
emtricitabine —	2015	77.542	botontkalking	3
carbamazepine —	1986	66.038	Epilepsie	12
insulin aspart —	2000	64.485	verlaagd bloedglucose	5
metronidazole —	1982	63.743	clostridium difficile infectie	15
letrozole —	1997	60.586	uitgezaaide borstkanker	2
fluticasone propionate and salmeterol xinafoate —	—	59.089	obstructieve luchtwegaandoening	0
dapagliflozin —	2014	56.693	diabetische ketoacidose	1
tenofovir alafenamide —	2015	41.643	botontkalking	0
naltrexone —	1984	39.971	Alcoholisme	17
insulin detemir —	2005	38.856	verhoogde bloedglucose	1
emtricitabine and tenofovir alafenamide —	—	35.132	botontkalking	0
fenofibrate —	2001	34.581	chronische nierziekte	11
canagliflozin —	2013	30.943	infectie van de diabetische voet	1
amoxicillin and clavulanate potassium —	—	26.702	Cholestase	5
atomoxetine —	2002	26.564	blefarospasme	19
azelastine —	2000	21.326	probleem met het aflevermechanisme van het product	9
cephalexin —	1971	21.106	nefrogene anemie	24
cobicistat —	2012	20.686	tandletsel	0
moxifloxacin —	2001	19.663	piepende ademhaling	38
moxifloxacin hydrochloride —	2001	19.655	piepende ademhaling	0
desoximetasone —	1980	18.541	anti-cyclisch citrulline peptide antistof positief	13
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	—	17.624	afgenomen botdichtheid	0
amitriptyline hydrochloride —	1977	16.938	pijn op de infusieplaats	0
trazodone hydrochloride —	1981	15.321	poging tot zelfdoding	0
thyroid, porcine —	—	10.359	Hartkloppingen	0
azelastine hydrochloride —	2000	10.154	probleem met het aflevermechanisme van het product	4
naltrexone hydrochloride —	1984	9.868	ontevredenheid patiënt over behandeling	1
beclomethasone dipropionate —	1976	9.839	neusklachten	7
colesevelam hydrochloride —	2000	9.134	geen bijwerking	0
triazolam —	1982	8.566	sopor	0
etodolac —	1996	5.914	chronische nierziekte	2
betamethasone valerate —	1967	4.388	winderigheid uit de vagina	0
clindamycin hydrochloride —	1970	3.461	maculopapulaire huiduitslag	3
sodium zirconium cyclosilicate —	2018	3.424	Abnormaal bloedkaliumgehalte	0
clindamycin phosphate topical —	—	3.384	hidradenitis	5
cefuroxime axetil —	1987	3.377	lymfedeem	0
levalbuterol hydrochloride —	1999	3.293	astma	0
norethindrone acetate and ethinyl estradiol and ferrous fumarate —	—	2.865	metrorragie	0
beclomethasone dipropionate hfa —	—	2.734	Probleem met afgiftesysteem van hulpmiddel	3
insulin lispro-aabc —	2020	1.984	irritatie op de infusieplaats	0
darunavir ethanolate and cobicistat —	—	1.744	botontkalking	0

Recall-geschiedenis · 50 geregistreerd

Datum	Klasse	Reden	Bedrijf
28 mei 2026	II	CGMP Deviations	Ajanta Pharma USA Inc
30 apr 2026	II	Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.	Safecor Health, LLC
20 apr 2026	II	Chemical contamination; presence of lead and lithium above specification	Acella Pharmaceuticals, LLC
26 feb 2026	II	Subpotent Drug	MACLEODS PHARMA USA, INC
31 dec 2025	II	Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.	Alvogen, Inc
18 dec 2025	II	Presence of particulate matter - Glass like particles.	Imprimis NJOF, LLC
13 okt 2025	II	Subpotent drug; Clavulanate Potassium component	Teva Pharmaceuticals USA, Inc
15 sep 2025	II	Failed Dissolution Specifications.	Amerisource Health Services LLC
5 aug 2025	II	Presence of foreign substance: identified as aluminum.	SUN PHARMACEUTICAL INDUSTRIES INC
29 jul 2025	II	Subpotent drug	Pfizer
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 jun 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
28 mei 2025	II	Lack of Assurance of Sterility	Apotex Corp.
23 mei 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
23 mei 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
13 mei 2025	II	Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules	AvKARE
9 mei 2025	II	Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule	Alembic Pharmaceuticals Limited
10 apr 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
10 apr 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
13 mrt 2025	I	LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.	Dr. Reddy's Laboratories, Inc.
13 mrt 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
13 mrt 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
7 mrt 2025	II	Super-Potent Drug: Out of specification potency results were obtained.	Mylan Institutional, Inc.
25 feb 2025	II	Presence of Foreign Tablets/Capsules.	A-S Medication Solutions LLC
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 jan 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
20 dec 2024	II	Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.	Lupin Pharmaceuticals Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
18 nov 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc
18 nov 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc

Class I = redelijke kans op ernstige schade · Class II = tijdelijk of omkeerbaar · Class III = onwaarschijnlijk schadelijk.

Registratiestatus

Sommige producten van A-S Medication Solutions zijn niet FDA-geregistreerd voor humaan gebruik. Voor ongeregistreerde stoffen (peptiden, SARMs zonder humane registratie) bestaat geen legitieme leverancier voor humaan gebruik. Het ontbreken van een inkooproute is de veiligheidsinformatie.